Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.Results: The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.Discussion: Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.Conclusion: It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.Trial registration number: NCT04973462.
Keywords: COVID-19; CT-scan; Coronavirus disease 2019; PCR; SARS-CoV-2; dyspnea; fever; oseltamivir; pneumonia; triazavirin.
On the 30th of January in the year 2020, the WHO announced that COVID-19 is a public health emergency event that has remarkable effects worldwide. In this scientific report, we compared whether triazavirin (TZV) 250 mg capsules and oseltamivir 75 mg capsules provide a better cure for COVID-19 patients with no side effects. A clinical study included two groups of COVID-19 patients who administered TZV 250 mg capsules three-times daily and oseltamivir 75 mg capsules twice per day for 7 days. The results showed that TZV provided better results in curing COVID-19 patients than oseltamivir. Patients administered TZV stayed in the hospital for 6.1 days, while those patients administered oseltamivir stayed for 8.4 days. Different scientific studies indicated that TZV is more effective in treatment of COVID-19. We can say that TZV provides better effect than oseltamivir. On the other hand, triazavirin can help in shortening the hospital length of stay, which will contribute to decreasing the pressure on the healthcare facilities.